Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.23.2    
  

 
 

AMENDMENT NO. 2    
  

        This Amendment No. 2, effective on the last date of signature, modifies and amends the Co-Promotion Agreement dated effective
November 26, 1997, as amended by the Amendment last executed on July 31, 2000 (together, the "AGREEMENT"), by and between Abbott Laboratories through its Ross Products Division
("ABBOTT"), and MedImmune, Inc. ("MEDIMMUNE"). 

 
 

WITNESSETH    
  

        WHEREAS, MEDIMMUNE and ABBOTT entered into a Co-Promotion Agreement dated effective November 26, 1997 in order to co-promote the
PRODUCT in the TERRITORY, and on July 31, 2000 entered into an Amendment effective for the 2000/2001 RSV season; 

        WHEREAS,
MEDIMMUNE and ABBOTT desire to further amend the AGREEMENT in order to provide special consideration for Synagis sales; 

        NOW
THEREFORE, in consideration of the promises and of the mutual covenants and agreements herein set forth, the parties hereto agree as follows: 

	1.
	Unless
otherwise stated capitalized terms have the same meaning herein as ascribed to them by the AGREEMENT.

	2.
	The
term of this Amendment No. 2 shall be for one RSV selling Season beginning on July 1, 2001 through June 30, 2002. Thereafter, the terms and conditions of the
Agreement shall again apply in all respects, without any affect from this Amendment No. 2.

	3.
	During
the term of this Amendment No. 2, the following reporting and payment compensation shall apply for the NET SALES of PRODUCT sold for use in the TERRITORY by MEDIMMUNE or
its AFFILATES as follows:

	a.
	Within
thirty (30) days after achievement of (CONFIDENTIAL TREATMENT REQUESTED) in net sales during the term of this Amendment No. 2 (i.e., the 2001/2002 RSV season),
ABBOTT shall pay to MEDIMMUNE (CONFIDENTIAL TREATMENT REQUESTED).

	b.
	ABBOTT
shall receive the following payment on NET SALES of PRODUCT. 

	% Royalty
	 	Threshold

	(CONFIDENTIAL TREATMENT REQUESTED)
	 	(CONFIDENTIAL TREATMENT REQUESTED)

	(CONFIDENTIAL TREATMENT REQUESTED)
	 	(CONFIDENTIAL TREATMENT REQUESTED)

	(CONFIDENTIAL TREATMENT REQUESTED)
	 	(CONFIDENTIAL TREATMENT REQUESTED)

	(CONFIDENTIAL TREATMENT REQUESTED)
	 	(CONFIDENTIAL TREATMENT REQUESTED)

	(CONFIDENTIAL TREATMENT REQUESTED)
	 	(CONFIDENTIAL TREATMENT REQUESTED)

        This
Amendment No. 2 and the AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter thereof and supersedes all prior agreements
and 

understandings in this respect. There shall be no amendments or modifications to this Amendment No. 2 or the AGREEMENT, except by a written document which is signed by both parties. 

	MEDIMMUNE, INC.	 	ABBOTT LABORATORIES

	

Name:	

/s/  MELVIN D. BOOTH      
 Melvin D. Booth	
 	

Name:	

/s/  GARY FLYNN      
 Gary Flynn
	

Title:	

President & Chief Operating Officer	
 	

Title:	

Sr. Vice President
	

Date:	

November 29, 2001	
 	

Date:	

November 16, 2001

QuickLinks

Exhibit 10.23.2

AMENDMENT NO. 2

WITNESSETHQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.26.1    
  

 
 

AMENDMENT TO THE DISTRIBUTION AGREEMENT    
  

        This Amendment to the Distribution Agreement ("AGREEMENT") is entered into as of April 28, 1999 (the "Effective Date") by and between
MedImmune, Inc. a Delaware corporation, having its principal place of business at 35 West Watkins Mill Road, Gaithersburg, MD 20878 ("MEDIMMUNE") and Abbott International, Ltd., a
Delaware corporation, having its principal place of business at 200 Abbott Park Road, Abbott Park, IL 60064. 

WITNESSETH  

        WHEREAS, MEDIMMUNE and Abbott International, Ltd. entered into a Distribution Agreement as of December 1, 1997 (the "DISTRIBUTION AGREEMENT"). 

        WHEREAS,
the parties desire to amend the DISTRIBUTION AGREEMENT. 

1.    DEFINITIONS    

	1.1
	All
fully capitalized terms used in this AGREEMENT have the same meaning as in the DISTRIBUTION AGREEMENT, except as otherwise defined above. 

2.    AMENDMENT    

	2.1
	Section 3.3
of the DISTRIBUTION AGREEMENT is amended to add the following Sections 3.3(f), 3.3(g), 3.3(h) and 3.3(i): 

        (f)    For
a period of two (2) years from the Effective Date of this AGREEMENT, the amount invoiced by MEDIMMUNE to ABBOTT under Section 3.3(a)(i)(A) and
3.3(a)(i)(B) shall be as follows: 

	(A)
	For
100 mg vials: (CONFIDENTIAL TREATMENT REQUESTED).

	(B)
	For
50 mg vials: (CONFIDENTIAL TREATMENT REQUESTED). 

        (g)  The
amounts paid under Section 3.3(f) shall be treated as being paid under Section 3.3(a)(i) for the purpose of determining the credit due under
Section 3.3(a)(ii) 

        (h)  With
respect to each vial for which ABBOTT is invoiced under Section 3.3(a)(i) as modified by Section 3.3(i), which is not sold by ABBOTT prior to
the expiration date therefor, by December 15th of each calendar year, for each unsold vial that has reached the expiration date during the period from
October 1st of the previous calendar year through September 30th of the applicable calendar year, ABBOTT shall pay the price therefor under
Section 3.2(a) using as NET SALES the weighted average of NET SALES of PRODUCT sold in the TERRITORY for the period from July 1stthrough September 30th
of the applicable calendar year, with the amount paid therefor under Section 3.3(f) being credited against the amount due under this Section 3.3(h). The payment under this
Section 3.3(h) shall include a report with respect to expired vials for the applicable period. 

        (i)    With
respect to each vial for which ABBOTT is invoiced under Section 3.3(a)(i) as modified by Section 3.3(f), within forty-five
(45) days following the end of each CALENDAR QUARTER, as part of the report under Section 3.3(b), ABBOTT shall provide to MEDIMMUNE a written country-by-country
report of the inventory and sales of such vials.— 

3.    EFFECT    

	3.1
	The
DISTRIBUTION AGREEMENT is amended as provided hereinabove as of the date first above written in accordance with Secion 14.3 of the DISTRIBUTION AGREEMENT. All other items and
provisions of the DISTRIBUTION AGREEMENT shall be unaffected by this AGREEMENT. 

        IN
WITNESS WHEREOF, the parties hereto have caused this AGREEMENT to be executed by their respective representatives hereunto duly authorized as of the day and year first above-written. 

	ABBOTT INTERNATIONAL, LTD.	 	MEDIMMUNE, INC.

	

By:	

/s/  ROBERT L. PARKINSON, JR.      
 Robert L. Parkinson, Jr.	
 	

By:	

/s/  MELVIN D. BOOTH      
 Melvin D. Booth
	Name:	Robert L. Parkinson, Jr.	 	Name:	Melvin D. Booth
	Title:	President & COO	 	Title:	President

JOINDER  

        The undersigned, Abbott Laboratories, an Illinois corporation, hereby consents to this AGREEMENT and joins in the execution of this AGREEMENT for the purpose of
obligating itself to the obligations and undertakings of Abbott International, Ltd., as set forth in this AGREEMENT. 

	ABBOTT LABORATORIES	 	 
	

By:	

/s/  ROBERT L. PARKINSON, JR.      
 Name: Robert L. Parkinson, Jr.

Title President & COO	
 	

 

QuickLinks

Exhibit 10.26.1

AMENDMENT TO THE DISTRIBUTION AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.26.2    
  

 
 

2nd AMENDMENT TO THE DISTRIBUTION AGREEMENT    
  

        This Second Amendment to the Distribution Agreement ("AGREEMENT"), is entered into as of October 8, 1999 by and between MedImmune, Inc., a Delaware
Corporation, having its principal place of business at 35 West Watkins Mill Road, Gaithersburg, MD 20878 ("MEDIMMUNE") and Abbott International, Ltd., a Delaware Corporation, having its
principal place of business at 200 Abbott Park Road, Abbot Park, IL 60064. 

WITNESSETH  

        WHEREAS, MEDIMMUNE and Abbott International, Ltd. entered into a Distribution Agreement as of December 1, 1997 that was subsequently amended on
April 28, 1999 (Distribution Agreement and Amendment collectively the "DISTRIBUTION AGREEMENT"). 

        WHEREAS,
the parties desire to further amend the DISTRIBUTION AGREEMENT; 

        1.    DEFINITIONS    

	1.1
	All
fully capitalized terms used in this AGREEMENT have the same meaning as in the DISTRIBUTION AGREEMENT, except as otherwise defined above. 

        2.    AMENDMENT    

	2.1
	Section 3.3.(a)(iii) is
deleted in its entirety and replaced with the following: 

(a)  The
minimum price ("MINIMUM PRICE") for the PRODUCT shall be the greater of I) (CONFIDENTIAL TREATMENT REQUESTED) per vial for the 100mg vials and (CONFIDENTIAL TREATMENT
REQUESTED) per vial for the 50mg vials (CONFIDENTIAL TREATMENT REQUESTED) for the corresponding PRODUCT or ii) (CONFIDENTIAL TREATMENT REQUESTED). If in any quarter of a CONTRACT YEAR, the
MINIMUM PRICE is greater than the price paid for the PRODUCT, then MEDIMMUNE shall notify ABBOTT and ABBOTT shall pay to MEDIMMUNE the difference between the MINIMUM PRICE and the price paid. In
addition, the MIMIMUM PRICE shall be reset for shipments in subsequent quarters to (CONFIDENTIAL TREATMENT REQUESTED). In the event that this paragraph 3.3.(a)(iii) becomes applicable
and this AGREEMENT is no longer economically viable to ABBOTT, then the parties shall discuss a change in PRODUCT pricing. 

	2.2
	Section 3.3.(a)(i) is
deleted in its entirety and replaced with the following: 

No
earlier than the date of delivery to the carrier, MEDIMMUNE may invoice ABBOTT in U.S. Dollars as set forth in subsections 3.3(i)(A-C) below, with payment being made within
forty-five (45) days of invoice, and MEDIMMUNE shall include with such invoice (CONFIDENTIAL TREATMENT REQUESTED) on, respectively, the 100mg vial size and the 50mg vial size. 

	2.3
	The
following shall be added as new Section 3.3 (j): 

MEDIMMUNE
shall keep, and shall cause each of its AFFILIATES to keep full and accurate books of account containing all particulars that may be necessary for the purpose of calculating (CONFIDENTIAL
TREATMENT REQUESTED). Such books of account shall be kept at their principal place of business and, with all necessary supporting data shall, for the two (2) years next following the end of the
calendar year to which each shall pertain be open for inspection by an independent certified public accountant selected by ABBOTT and reasonably acceptable to MEDIMMUNE upon verifying such
(CONFIDENTIAL TREATMENT REQUESTED) or compliance with this AGREEMENT, but in no event more than once in each calendar year. All information and data offered shall be used only for such purpose. In the
event that such 

inspection shall indicate that in any calendar year the (CONFIDENTIAL TREATMENT REQUESTED) reported as owed and/or paid by MEDIMMUNE are at least five percent (5%) greater than those which were
actually owed and/or paid by MEDIMMUNE, then MEDIMMUNE shall pay the cost of such inspection. All amounts reported as owed and/or paid for (CONFIDENTIAL TREATMENT REQUESTED) which are in excess of the
amounts actually owed and/or paid by MEDIMMUNE on the PRODUCT shall immediately be credited against any and all amounts due and owing by ABBOTT to MEDIMMUNE under this AGREEMENT. 

        3.    EFFECT    

	3.1
	The
DISTRIBUTION AGREEMENT is amended as provided hereinabove as of July 1, 1999 in accordance with Section 14.3 of the DISTRIBUTION AGREEMENT. All other items and
provisions of the DISTRIBUTION AGREEMENT shall be unaffected by this AGREEMENT. 

        IN
WITNESS WHEREOF, the parties have each caused this AGREEMENT to be signed and delivered by its duly authorized officer or representative as indicated below. 

	ABBOTT INTERNATIONAL, LTD	 	MEDIMMUNE, INC.

	

By:	

/s/  WILLIAM G. DEMPSEY      
 William G. Dempsey	
 	

By:	

/s/  MELVIN D. BOOTH      
 Melvin D. Booth
	Name:	William G. Dempsey	 	Name:	Melvin D. Booth
	Title:	Senior Vice President

Abbott International	 	Title:	President

JOINDER  

        The undersigned, Abbott Laboratories, an Illinois Corporation, hereby consents to this AGREEMENT and joins in the execution of this AGREEMENT for the purpose of
obligating itself to the obligations and undertakings of Abbott International Ltd., as set forth in this AGREEMENT. 

	ABBOTT LABORATORIES	 
	

By:	

/s/  WILLIAM G. DEMPSEY      
 Name: William G. Dempsey

Title: Senior Vice President, Abbott International, Abbott Laboratories

Dated:    October 13, 1999	

 

QuickLinks

Exhibit 10.26.2

2nd AMENDMENT TO THE DISTRIBUTION AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]